Pier Capital LLC Trims Position in Omnicell, Inc. (NASDAQ:OMCL)

Pier Capital LLC cut its stake in Omnicell, Inc. (NASDAQ:OMCL) by 27.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 96,863 shares of the company’s stock after selling 37,511 shares during the quarter. Pier Capital LLC’s holdings in Omnicell were worth $4,312,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. EntryPoint Capital LLC bought a new position in shares of Omnicell during the fourth quarter valued at approximately $244,000. Segall Bryant & Hamill LLC purchased a new stake in shares of Omnicell in the 4th quarter worth $649,000. Prudential Financial Inc. grew its stake in shares of Omnicell by 26.4% during the 4th quarter. Prudential Financial Inc. now owns 231,053 shares of the company’s stock valued at $10,286,000 after acquiring an additional 48,193 shares during the period. Advantage Alpha Capital Partners LP boosted its position in shares of Omnicell by 14.9% in the fourth quarter. Advantage Alpha Capital Partners LP now owns 52,041 shares of the company’s stock worth $2,317,000 after purchasing an additional 6,753 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after buying an additional 28,573 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Stock Up 3.5 %

Omnicell stock opened at $35.14 on Tuesday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 130.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The business’s 50-day moving average price is $39.63 and its 200 day moving average price is $42.83. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Monday. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.